Evidence map›Paper›PMID 40423317›Full record

ArticleToxins2025

Development and Preclinical Testing of a Novel Neurodenervant in the Rat: C3 Transferase Mitigates Botulinum Toxin's Adverse Effects on Muscle Mechanics.

Cemre Su Kaya Keles, Zeynep D Akdeniz Dogan, Can A Yucesoy

Abstract read
In one paragraph

Article in Toxins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Cemre Su Kaya KelesInstitute of Biomedical Engineering, Boğaziçi University, 34684 Istanbul, Turkey.ORCID 0000-0001-7345-0772
Zeynep D Akdeniz DoganDepartment of Plastic, Reconstructive, and Aesthetic Surgery, Marmara University, 34854 Istanbul, Turkey.ORCID 0000-0003-0891-5558
Can A YucesoyInstitute of Biomedical Engineering, Boğaziçi University, 34684 Istanbul, Turkey.ORCID 0000-0002-6238-4420

Funding

Scientific and Technological Research Council of Turkey 116S393Scientific and Technological Research Council of Turkey 22AG016
6 · The paper itself

Abstract

Spasticity, characterized by elevated muscle tone, is commonly managed with botulinum toxin type A (BTX-A). However, BTX-A can paradoxically increase passive muscle forces, narrow muscles' length range of force exertion (l

Indexed as

Botulinum Toxins, Type AMuscle, SkeletalMuscle SpasticityNeuromuscular AgentsAnimalsExtracellular MatrixMaleMuscle ContractionRatsRats, WistarBotulinum Toxins, Type ANeuromuscular Agentsbotulinum toxin type AC3 transferaseextracellular matrix stiffnessmuscle forcerange of motionspasticity management

Identifiers

PMID40423317
PMCPMC12115743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.